Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million.

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Read about Recursion Pharmaceuticals Inc Class A (RXRX:XNAS) stock and today's latest news and financial updates.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of These 10 Stocks Are Making Big Moves. Recursion Pharmaceuticals ...

Check out our RXRX stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley assumed coverage of the company’s stock with an “Equal ...

Find the latest on short interest, settlement dates, average share volume, and days to cover for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.

Local news coverage of La Jolla, including local news and events, business listings, discussions, announcements, photos and videos.